Anagliptin vs Gemigliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Anagliptin · Suiny

Marketed by Sanwa Kagaku Kenkyusho and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT01529541 · Phase 3 · completed

The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.

Next expected readout: March 2027 · NCT07442006 (registry estimate)

Reported efficacy

The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)

Result source: NCT01529528

Gemigliptin · Zemiglo

Marketed by LG Chem and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT01787396 · Phase 3 · completed

This was a randomized, quadruple-blind trial (n=433) with three arms: gemigliptin plus metformin, gemigliptin alone (with a matching metformin placebo), and metformin alone (with a matching gemigliptin placebo). The primary endpoint, HbA1c change at 24 weeks, favored the combination over either monotherapy.

Reported efficacy

Changes from baseline HbA1c at week 24 (Baseline (week 0) and week 24): LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%. (met)

Result source: NCT03842267

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnagliptinGemigliptin
HbA1c, change-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
-0.8% vs 0.4%a−1.2 vs placebowk 12NCT01968044
2 other results
  • -2.1% vs -1.5% gemigliptin 50mg qd + metformin combination · wk 24 · Phase 3 · primary NCT01787396
  • -1.2% vs -1.5% wk 24 · Phase 3 · primary NCT01787396
Body weight, change (kg)—Not posted · NCT01529528—Not posted · NCT01787396
HbA1c below 7%—Not posted · NCT01529528—Not posted · NCT01787396
Fasting plasma glucose, change—Not posted · NCT01529528—Not posted · NCT01787396
3-point MACE (% with event)—Not posted · NCT01529528—Not posted · NCT01787396

HbA1c, change

Anagliptin
-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
Gemigliptin
-0.8% vs 0.4%a−1.2 vs placebowk 12NCT01968044
2 other results
  • -2.1% vs -1.5% gemigliptin 50mg qd + metformin combination · wk 24 · Phase 3 · primary NCT01787396
  • -1.2% vs -1.5% wk 24 · Phase 3 · primary NCT01787396

Body weight, change (kg)

Anagliptin
—Not posted · NCT01529528
Gemigliptin
—Not posted · NCT01787396

HbA1c below 7%

Anagliptin
—Not posted · NCT01529528
Gemigliptin
—Not posted · NCT01787396

Fasting plasma glucose, change

Anagliptin
—Not posted · NCT01529528
Gemigliptin
—Not posted · NCT01787396

3-point MACE (% with event)

Anagliptin
—Not posted · NCT01529528
Gemigliptin
—Not posted · NCT01787396
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Gemigliptin

HbA1c -0.7% @ 24wkgemigliptin 50 mg
absolute change · percentage points
No placebo or comparator arm
NCT02831361 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-0.66% @ 24wk
NCT03842267 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Gemigliptin's landscape